Ipsen: latest news - GoINPHARMA
Saturday, 19 January 2019 - 9:39

Ipsen

Positive Phase III results for Ipsen’s liver cancer therapy, shares soar

Ipsen and its partner Exelixis have announced they have interrupted the Phase III Celestial clinical trial, since the investigational therapy Cabometyx (cabozantinib) has reached its endpoints earlier than expected. Specifically, Cabometyx has been reported to provide a statistically significant improvement…

Ipsen focuses on oncology to keep growing

France-based group Ipsen is experiencing an extremely positive phase, confirming that the strategic decision to focus on oncology has been right. Oncology products account for 60% of the company’s revenues now, and the recent approval of Xermelo (neuroendocrine cancer) has…

Sanofi to sell Buscopan and 4 other OTCs to Ipsen for €83m

France-based Ipsen has bought for €83m five consumer healthcare products from Sanofi. These are the analgesic Prontalgine, the antispasmodic Buscopan, the laxative Suppositoria Glycerini and and the cough and flu products Mucothiol and Mucodyne. The products will no longer be…